AKT1 and metabolic disease: YAP and TAZ, effectors of the Hippo pathway, can upregulate components of the PI3K/Akt pathway, including GAB2 and IRS2, which enhance PI3K/Akt signaling and promote cell proliferation and survival in cancers and metabolic diseases [94, 95, 97, 115].